Chungbuk National University Hospital

Cheongju-si, Chungcheongbukdo 28644

2 studies enrolling now · 6 studies all time

What they study most

Alpha-fetoprotein (AFP)-Producing Gastric Cancer, EGFR Activating Mutation, EGFR Mutation-Related Tumors, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, HR+/HER2- Breast Cancer, Limited Stage Small Cell Lung Cancer, Local Advanced Hepatocellular Carcinoma, Lung Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Non-small Cell Lung Cancer, NSCLC

Studies at this site

• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease — Recruiting now
• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer — Stopped early
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — Running, not enrolling
• Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer — Completed